IMMXImmix Biopharma, Inc.

1. Sep 30, 2026On September 29, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 11,363,637 …Other event · Form 8-K
2. Sep 29, 2026On September 29, 2026, the Company announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response (“CR”) rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee.Regulation FD disclosure · Form 8-K
3. Jul 20, 2026As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company.Other event · Form 8-K
4. May 21, 2026On May 21, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an …Other event · Form 8-K
5. May 21, 2026On May 21, 2026, the Company announced an update from the Phase 2 NEXICART-2 NXC-201 clinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis patients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative patients have …Regulation FD disclosure · Form 8-K
6. Mar 30, 2026On March 30, 2026, the Company issued a press release announcing that the enrollment for its NEXICART-2 clinical trial of NXC-201 is complete, with topline results expected in Q3 2026.Regulation FD disclosure · Form 8-K
7. Mar 25, 2026On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to …Material agreement entered · Form 8-K
8. Dec 8, 2025Underwritten Registered Offering On December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto (the “Underwriters”) …Material agreement entered · Form 8-K
9. Dec 8, 2025On December 7, 2025, the Company announced positive phase 2 NXC-201 results in an oral presentation at the American Society of Hematology’s ASH 2025 Annual Meeting, presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center.Regulation FD disclosure · Form 8-K
10. Nov 26, 2025This Current Report on Form 8-K is being filed solely to file newly dated consents of KMJ Corbin & Company LLP, formerly the independent registered public accounting firm of Immix Biopharma, Inc. (the “Company”), and Crowe LLP, currently the independent registered accounting firm of the Company, each dated November …Other event · Form 8-K
11. Sep 8, 2025On September 5, 2025, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company sold to the …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.